<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052985</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01868-43</org_study_id>
    <nct_id>NCT03052985</nct_id>
  </id_info>
  <brief_title>Materiovigilance After Urinary Incontinence or Prolapse Surgery</brief_title>
  <acronym>VIGI-MESH</acronym>
  <official_title>Observatory of Materiovigilance After Surgery of Urinary Incontinence or Prolapse in Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agence Nationale de sécurité du Médicament</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observatory of Materiovigilance After Surgery of Urinary Incontinence or Prolapse in Women
      Implantable medical devices (meshes) used in pelvic organ prolapse surgery (genital prolapse,
      rectal prolapse), or incontinence surgery may be source of severe complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONAL Implantable medical devices (meshes) used in pelvic organ prolapse surgery (genital
      prolapse, rectal prolapse), or incontinence surgery may be source of severe complications.

      MAIN OBJECTIVE Estimate the incidence of severe complications during or after surgery of
      urinary incontinence or pelvic organ prolapse in adult women depending on the type of surgery
      performed.

      SECONDARY OBJECTIVES Estimate the incidence of severe complications after urinary
      incontinence or prolapse surgery as a function of time since surgery.

      Compare the incidence rates of severe complications considering the type of procedure (with
      or without mesh, vaginal or laparoscopic, etc.), comorbidities, mesh type, surgeon
      experience, and surgical volume centre.

      Report the health and satisfaction of operated women. Estimate the risk of revision surgery
      for failure or recurrence.

      MAIN OUTCOME Per- and post-operative complications (less than 12 months after surgery), or
      late (after 12 months) severe (grade III or higher according to the Clavien-Dindo
      classification)

      OTHER OUTCOMES Time lapse of occurrence of severe complications Surgical recovery for failure
      or recurrence Health and perceived improvement (OMS, EQ5D, an PGI-I questionnaires)

      DESIGN Prospective multicentre cohort allowing the constitution and analysis of an
      observatory off surgery for genital prolapse, rectal prolapse and urinary stress incontinence
      in women.

      INCLUSION CRITERIA

        -  Operated for urinary incontinence, genital prolapse, or rectal prolapse in one of the
           centres participating in the observatory

        -  18 years old or more.

      SUBJECTS NUMBER Estimated at 3000 per year during 5 years in 18 participating centres

      STUDY LENGTH Duration of the inclusion period: 2 years with the initial grant from ANSM
      (Agence Nationale de Sécurité du Médicament et des produits de santé, French Medicines and
      Healthcare Products Regulatory Agency), after new funding by ANSM 5 years of inclusion in
      total.

      Duration of participation of subjects: 2 years with grant from ANSM, after the new funding by
      ANSM 10 years.

      Total duration of the study: 3 years with the grant from ANSM, 15 years with the new funding.

      ANALYSIS PLANNED The one-year analysis will be based on multivariate logistic regression
      analysis (considering confounding factors). The 10-year (or intermediate-term) analysis will
      use survival analysis methods to account for delays in complications: Kaplan-Meier curves;
      Model of Cox proportional hazards.

      PERSPECTIVES The observatory should make it possible to precise the tolerance and the short-
      and long-term consequences of the use of these implantable devices (meshes) in pelvic organ
      prolapse or incontinence surgery in women and to specify the risk factors for severe
      complications.

      The observatory will enable to make comparisons between the different types of meshes and
      different surgical procedures, and to identify those that may present problems.

      Clinical practice recommendations may be issued as well as standards for marketing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Anticipated">February 14, 2032</completion_date>
  <primary_completion_date type="Anticipated">February 14, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of severe complications</measure>
    <time_frame>10 years</time_frame>
    <description>Grade III or more according to Clavien-Dindo classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time lapse of occurrence of severe complications</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical recovery for failure or recurrence</measure>
    <time_frame>10 years</time_frame>
    <description>Number participent with new revision surgery for failure Number participent with new revision surgery for recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health and perceived improvement</measure>
    <time_frame>10 years</time_frame>
    <description>Scale OMS/ ECOG Eastern Cooperative Oncology Groupone covers six values, from 0 to 5, where 0 represents a good state of health and 5 the death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health and perceived improvement</measure>
    <time_frame>10 years</time_frame>
    <description>EQ5D is a standardised measure of health status developed
Each of the 5 dimensions comprising the EQ-5D descriptive system is divided into 5 levels of perceived problems :
Level 1 : indicating no problem
Level 2 : indicating slight problems
Level 3 : indicating moderate problems
Level 4 : indicating severe problems
Level 5 : indicating extreme problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health and perceived improvement</measure>
    <time_frame>10 years</time_frame>
    <description>PGI-I, Patient Global Impression of Improvement, is a transition scale that is a single question asking the patient to rate their urinary tract condition now, as compared with how it was prior to before beginning treatment on a scale from 1. Very much better to 7. Very much worse.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <condition>Rectal Prolapse</condition>
  <condition>Urinary Stress Incontinence</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>urinary incontinence, pelvic organ or rectal prolapse surgery</intervention_name>
    <description>The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women operated for urinary incontinence, pelvic organ prolapse, or rectal prolapse in one
        of the centres participating in the observatory, aged 18 years old or more.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Operated for urinary incontinence, pelvic organ prolapse, or rectal prolapse in one of
             the centres participating in the observatory

          -  18 years old or more.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier FRITEL, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucie Merlet, CRA</last_name>
    <phone>+33 (0)5.49.44.30.59</phone>
    <email>lucie.merlet@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier de Béthune</name>
      <address>
        <city>Béthune</city>
        <zip>62400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elvis NKOUNKOU, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne-Cécile Pizzoferrato, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Camille Guérin</name>
      <address>
        <city>Châtellerault</city>
        <zip>86106</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Caroline Carlier-Guerin, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Antoine-Béclère</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xavier Deffieux, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>630003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandrine Campagne-Loiseau, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Debodinance, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital La Rochelle- Ré- Aunis</name>
      <address>
        <city>La Rochelle</city>
        <zip>17000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Ferry, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michel Cosson, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital St Vincent De Paul</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Philippe Lucot, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique BEAUSOLEIL</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laure Panel, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de NANCY</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent Bresler, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thibault Thubert, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Carémeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Renaud De Tayrac, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint-Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François Haab, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Poissy-St-Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arnaud Fauconnier, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Fritel, PhD, MD</last_name>
      <phone>549443360</phone>
      <phone_ext>+33</phone_ext>
      <email>xavier.fritel@outlook.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Fritel, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>37200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian SAUSSINE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pierre-Olivier Bosset, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>medical devices (meshes)</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Prolapse</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

